A new oral medication has demonstrated a significant reduction in low-density lipoprotein (LDL) cholesterol, commonly known as ‘bad’ cholesterol, in a major clinical trial. The trial results showed the pill reduced LDL levels by an average of 60% in participants over a 12-week period. The drug works by targeting a specific protein involved in cholesterol regulation, offering a potential new treatment option for patients who cannot tolerate or do not respond adequately to existing statin therapies. Researchers noted the treatment was generally well-tolerated, with the most common side effects being mild and transient. Further studies are planned to assess the drug’s long-term safety and its impact on cardiovascular events like heart attack and stroke. For the full details, read the complete article at https://www.sciencedaily.com/releases/2026/03/260321012659.htm.